Evidence map›Paper›PMID 35088292›Full record

Observational studyEndocrine2022

Angiogenic factors as prognostic markers in neuroendocrine neoplasms.

Giulia Puliani, Franz Sesti, Emanuela Anastasi, Monica Verrico, Maria Grazia Tarsitano, Tiziana Feola, Federica Campolo, Cira Rosaria Tiziana Di Gioia, Mary Anna Venneri, Antonio Angeloni and 6 more

Abstract readObservational Study
PubMed Publisher
In one paragraph

Observational study in Endocrine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.7field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 4 institutions in 1 country.

Giulia PulianiDepartment of Experimental Medicine, Sapienza University of Rome, Rome, Italy.
Franz SestiDepartment of Experimental Medicine, Sapienza University of Rome, Rome, Italy.
Emanuela AnastasiDepartment of Experimental Medicine, Sapienza University of Rome, Rome, Italy.
Monica VerricoMedical Oncology Unit A, Department of Radiological, Oncological and Pathological Sciences, Sapienza University of Rome, Rome, Italy.
Maria Grazia TarsitanoDepartment of Experimental Medicine, Sapienza University of Rome, Rome, Italy.
Tiziana FeolaDepartment of Experimental Medicine, Sapienza University of Rome, Rome, Italy.
Federica CampoloDepartment of Experimental Medicine, Sapienza University of Rome, Rome, Italy.
Cira Rosaria Tiziana Di GioiaDepartment of Radiological, Anatomopathological and Oncological Sciences, Sapienza University of Rome, Rome, Italy.
Mary Anna VenneriDepartment of Experimental Medicine, Sapienza University of Rome, Rome, Italy.
Antonio AngeloniDepartment of Experimental Medicine, Sapienza University of Rome, Rome, Italy.
Marialuisa AppetecchiaOncological Endocrinology Unit, IRCCS Regina Elena National Cancer Institute, Rome, Italy.
Andrea LenziDepartment of Experimental Medicine, Sapienza University of Rome, Rome, Italy.
Andrea Marcello IsidoriDepartment of Experimental Medicine, Sapienza University of Rome, Rome, Italy.
Antongiulio FaggianoEndocrinology Unit, Department of Clinical and Molecular Medicine, Sant'Andrea Hospital, Sapienza University of Rome, Rome, Italy.
Elisa GiannettaDepartment of Experimental Medicine, Sapienza University of Rome, Rome, Italy. elisa.giannetta@uniroma1.it.ORCID http://orcid.org/0000-0003-3614-6151
Nettare Unit
Sapienza University of Rome · ITIstituti di Ricovero e Cura a Carattere Scientifico · ITIstituto Neurologico Mediterraneo · ITOspedale Santa Maria Goretti · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeAngiogenic markers in neuroendocrine neoplasms (NENs) have recently received increasing attention, but their clinical role remains unclear. The aim of this study was to evaluate the role of angiogenic markers in NEN aggressiveness and prognosis.

methodsWe performed a prospective observational study including 46 consecutive patients with proven NENs of pulmonary (45.65%) and gastro-entero-pancreatic (GEP) (54.35%) origin and 29 healthy controls. Circulating pro-angiogenic factors were measured by ELISA assay. ANG2 tissue expression was evaluated in a subgroup of ten patients by immunohistochemistry.

resultsThe study demonstrated a significantly higher level of ANG2, ANG1, sTIE2, and PROK2 in patients affected by NENs compared to controls. In the NENs' group we measured that: (i) ANG2 levels were higher in poorly vs well-differentiated NENs: 4.85 (2.75-7.42) vs 3.16 (1.66-6.36) ng/ml, p = 0.046 and in tumor stage 3-4 compared to stage 1-2: 4.24 (2.66-8.72) vs 2.73 (1.53-5.70), p = 0.044; (ii) ANG2 and PROK2 were significantly higher in patents with progressive disease compared to stable disease: ANG2 = 6.26 (3.98-10.99) vs 2.73 (1.65-4.36) pg/ml, p = 0.001; PROK2 = 29.19 (28.42-32.25) vs 28.37 (28.14-28.91) pg/ml, p = 0.035. Immunohistochemistry confirmed ANG2 expression in tumor specimens.

conclusionsWe documented higher levels of angiogenic markers in NENs, with an association between ANG2 serum levels and NENs morphology and staging. In both GEP and lung NENs, ANG2 and PROK2 are higher in case of tumor progression, suggesting a potential role as prognostic markers in NENs patients.

Indexed as

Intestinal NeoplasmsNeuroendocrine TumorsPancreatic NeoplasmsStomach NeoplasmsAngiogenesis Inducing AgentsHumansPrognosisAngiogenesis Inducing AgentsAngiogenesisAngiopoietinNeuroendocrine neoplasmNeuroendocrine tumorPrognostic markerPROK2

Identifiers

PMID35088292
OpenAlexW4210487085

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.